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Cancer is a leading cause of death worldwide and sustained focus is on the discovery and development of
newer and better tolerated anticancer drugs especially from plants. The sulforhodamine B (SRB) in vitro
cytotoxicity assay, sarcoma-180 (S-180) ascites and solid tumor, and L1210 lymphoid leukemia in vivomodels
were used to investigate the anticancer activity of root extracts of Aristolochia ringens Vahl. (Aristolochiaceae;
馬兜鈴mǎ dou líng). AR-A001 (IC50 values of 20 mg/mL, 22 mg/mL, 3 mg/mL, and 24 mg/mL for A549, HCT-116,
PC3, andTHP-1 cell lines, respectively), andAR-A004 (IC50 values of 26mg/mL,19.5 mg/mL,12 mg/mL, 28 mg/mL,
30 mg/mL, and 22 mg/mL for A549, HCT-116, PC3, A431, HeLa, and THP-1, respectively), were observed to be
signiﬁcantlyactive invitro. PotencywashighestwithAR-A001andAR-A004 forPC3with IC50values of 3mg/mL
and 12 mg/mL, respectively. AR-A001 and AR-A004 produced signiﬁcant (p < 0.05e0.001) dose-dependent
inhibition of tumor growth in the S-180 ascites model with peak effects produced at the highest dose of
120mg/kg. Inhibitionvalueswere79.51%and89.98% forAR-A001andAR-A004, respectively. In theS-180solid
tumor model, the inhibition of tumor growth was 29.45% and 50.50% for AR-A001 (120mg/kg) and AR-A004
(110 mg/kg), respectively, compared to 50.18% for 5-ﬂuorouracil (5-FU; 20 mg/kg). AR-A001 and AR-A004
were also signiﬁcantly active in the leukemia model with 211.11% and 155.56% increase in mean survival
time (MST) compared to a value of 211.11% for 5-FU. In conclusion, the ethanolic (AR-A001) and dichlor-
omethane:methanol (AR-A004) root extracts of AR possess signiﬁcant anticancer activities in vitro and in vivo.
Copyright © 2015, Center for Food and Biomolecules, National Taiwan University. Production and hosting
by Elsevier Taiwan LLC. All rights reserved.1. Introduction
Cancer is a deadly disease and about one in four people will get it
in some form during their lifetime; at the present time, about one in
ﬁve of all deaths are due to cancer.1 Normal diploid human cells
multiply for a ﬁnite number of generations and then enter a state of
replicative senescence, but cancer cells can proliferate indeﬁnitely.2
About 12.7 million cancer cases and 7.6 million cancer deaths arelogy, Therapeutics and Toxi-
edicine, University of Lagos,
sion, Indian Institute of Inte-
esearch, Jammu-Tawi 180001,
ndele), dmmondhe@iiim.ac.in
for Food and Biomolecules,
molecules, National Taiwan Univeestimated tohaveoccurred in2008; of these,56%of the cases and64%
of the deaths occurred in the economically developing world.3 Sur-
gery is useful in removing visible tumors, butmay leave smaller nests
of cancer cells in the patient which continue to proliferate, while
radiation therapy is relatively imprecise as it can kill both cancer cells
and normal cells, and thus has toxic side effects which may them-
selves be lethal to the patients.2 Chemotherapywith antiproliferative
agents, including alkylating agents, antimetabolites, antibiotics, and
hormones, apart from being complementary to surgical intervention
and radiotherapy, is essential in cases of metastasis.
According to Sikora et al,4 although 92 approved anticancer
drugs are available for the treatment of > 200 different tumor en-
tities, effective therapies for most of these tumors are lacking.
Furthermore, out of the 92 registered drugs, 17 are considered by
oncologists to be more broadly applicable and 12 additional agents
are perceived as having certain advantages in some clinical set-
tings.5 Limitations in the application of chemotherapeutic agents
include toxicity, manifestation of deleterious side-effects, and arsity. Production and hosting by Elsevier Taiwan LLC. All rights reserved.
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are geared towards the discovery and development of newer and
better tolerated anticancer drugs, especially from natural products,
mainly plants. New targets for anticancer agent development are
rapidly emerging in the post-genome era, and improvements in
protein structure determination, combinatorial chemistry, and
high-throughput small-molecule screens may accelerate the gen-
eration of new agents to be studied in the clinic.6
Aristolochia ringens Vahl. (Aristolochiaceae (AR); 馬兜鈴 mǎ dou
líng) is a glabrous bushy climber native of tropical America, intro-
duced to most West African countries as a garden ornamental, and
has become naturalized in roadside bush in Sierra Leone, Ghana,
Nigeria,7 and DR Congo.8 The plant is commonly called “Dutchman's
pipe”and “Snakework”but localnames inNigeria include “Ako-igun”
(Yoruba, Southwest Nigeria) and “Dumandutsee” (Hausa, Northern
Nigeria). Preparations of the leaves, roots, andwhole plant have been
reported to be used traditionally in Nigeria for the treatment of
diverse ailments including guinea worm, skin diseases, typhoid,
sores, as an antidote to snake poison, an emmenagogue, and an
anthelmintic remedy.9 In South America, the plant is used for the
treatmentof snakebites, fever, ulcers, and colic,10while the root of the
plant is used in Senegal as an antidote for snakebites.11 Sonibare and
Gbile12 stated that the root of the plant is used in Southwest Nigeria
for the treatmentof asthma,while Soladoye et al13 reported its use for
the treatment of hemorrhoids. The decoction/infusion of the root of
the plant is also used as an antidiabetic.14 Antiinﬂammatory15 and
antitrypanosomal16 activities of the plant have also been reported.
Based on the fact that some species of the genus Aristolochia
have been reported to possess anticancer activity,17e19 this study
was designed to investigate the anticancer activity of root extracts
of AR using in vitro and in vivo methods.
2. Materials and methods
2.1. Plant material
AR roots were obtained from a local herbal market in Mushin,
Lagos State, Nigeria. The plant material was identiﬁed and
authenticated by Mr. T.K. Odewo of the Department of Botany and
Microbiology, University of Lagos, Lagos, Nigeria, where a herbari-
um specimen was deposited with voucher number LUH 4061.
2.2. Extraction
Fresh roots of AR were cut into pieces and air-dried until a con-
stant weight was attained. The dried materials were milled and
divided into four portions of 100 g each. Three portions were
separately macerated in about 1500mL of alcohol (95% ethanol: AR-
A001), hydro-alcohol (ethanol and water, 1:1; AR-A002), and
distilled water (AR-A003). Maceration was sustained for 3 hours
with mechanical stirring (Heidolph RZR 2051 Control; Heidolph
Instruments GmbH & Co. KG, Schwabach, Germany) at 400  g.
Filtration was thereafter carried out using Whatman ﬁlter paper
(150 mm). Residues were remacerated ( 2) to achieve exhaustive
extraction. The combined ﬁltrate of the alcoholic (AR-A001) and
hydroalcoholic (AR-A002) extracts were concentrated using a Hei-
dolph Rotavapor (LABORATA 4000) at 120  g and 40C. The com-
bined ﬁltrate of the aqueous extract was lyophilized (AR-A003). The
fourth portion of 100 g of the powdered plant material was put into
2000mL separating funnels with the bottom lined with cottonwool
and 1 L of dichloromethane:methanol (DCM:MeOH; 70:30) was put
into the separating funnel. Twenty-four hours later, the solvent
mixture was drained and the extraction liquid was ﬁltered using
Whatman ﬁlter paper (150mm). On the 2nd day and 3rd day, 600 mL
of the DCM:MeOH solvent mixture was added to the separatingfunnel, drained 24 hours after, and ﬁltered. The combined
DCM:MeOH extract was concentrated with a Rotavapor without
vacuum (AR-A004). All dried extracts were weighed and stored in a
desiccator. The yields of the extracts were 4.41% (AR-A001), 16.00%
(AR-A002), 11.88% (AR-A003), and 5.93% (AR-A004).
2.3. Chemicals
The chemicals used in this study include RPMI-1640, minimum
essential medium, fetal calf serum, trypsin, trypan blue, ethanol,
penicillin, streptomycin, gentamycin, dimethyl sulfoxide (DMSO),
sulforhodamine B (SRB), mitomycin-C, paclitaxel, 5-ﬂuorouracil (5-
FU; Sigma Chemical Co., St Louis, MO, USA), phosphate buffer saline
(Merck, Darmstadt, Germany); trichloroacetic acid (TCA), distilled
water, sodium hydroxide, Tris-EDTA buffer, Tris buffer (Hi-Media,
Mumbai, India), acetic acid, sodium bicarbonate, hydrochloric acid
(Rankem, New Delhi, India), isopropanol (Sisco, Mumbai, India),
and Tris-acetate-EDTA buffer. All other chemicals used in this study
were purchased locally and were of analytical grade.
2.4. Cell lines and cell cultures
The human cancer cell lines used in this study, including A549
(lung), HCT-116 (colon), PC3 (prostate), A431 (skin), HeLa (cervix),
and THP-1 (leukemia) were obtained from the National Center for
Cell Science, Pune, India, or the National Cancer Institute, Frederick,
MD, USA. The cells were grown and maintained in appropriate
medium, pH 7.4, supplemented with 10% fetal calf serum, glutamine
(2mM), penicillin (100 units/mL), and streptomycin (100 mg/mL).
The cell cultures were grown in a carbon dioxide incubator (Her-
aeus, GmbH, Germany) at 37C with 90% humidity and 5% CO2.20,21
2.5. Animals
The animals used in this study, including inbred BALB/c and DBA/
2, outbred Swiss albino, and F1 hybrid CDF1 mice, were obtained
from the animal facility of the Indian Institute of Integrative Medi-
cine, Jammu, India and maintained at 22 ± 2C with 20e25 com-
plete air changes with 100% fresh air. Relative humidity was
maintained at 50e60%. Animals were fed with commercially avail-
able pelleted feed (M/s Ashirwad Industries, Chandigarh, India) and
were provided autoclaved water ad libitum. Animals were housed in
transparent polycarbonate ﬁlter top cages in animal isolator cabins.
The animals selected for the experiments were in the weight range
of 18e23 g (about 2months of age) andwere observed to be healthy
and free from any disease. All of the animals selected for individual
experiments were of the same sex and strain. The protocols adopted
in this study were approved by the Institutional Animal Ethics
Committee, Indian Institute of Integrative Medicine, Jammu, India.
2.6. In vitro cytotoxicity against human cancer cell lines
The in vitro cytotoxicity of the extracts of ARwas determined by
a semiautomated assay using SRB.20e22 The human cancer cell lines
were grown in tissue culture ﬂasks at 37C in an atmosphere of 5%
CO2 and 90% relative humidity in complete growth medium. Flasks
with subconﬂuent stage of growth were selected and cells were
harvested by treatment with trypsin-EDTA. The numbers of cells/
mL of suspension were counted using hemocytometer. The cell
density was adjusted to 10,000 cells/100 mL, or as appropriate for
each cell line, in the cell suspension. A volume of 100 mL of cell
suspension was added to each well of 96 well plates with the help
of handy-step. The plates were incubated at 37C in an atmosphere
of 5% CO2 and 90% relative humidity for 24 hours. Thereafter, 100 mL
of aworking solution of each test material was added to thewells of
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were prepared in DMSO and serially diluted with complete growth
medium such that 100 mL of working solutions of each extract gave
concentrations of 10 mg/mL, 30 mg/mL, and 100 mg/mL [ﬁnal DMSO
concentrationwas from 0.5% (highest) to 0.001% (lowest)] added to
the 96-well cell culture plates. The 96-well cell culture plates
contained appropriately seeded cells (e.g., 8000 cells/100 mL for
HCT-116 and A431; 10,000 cells/100 mL for HeLa), and all vehicle
controls contained the same concentration of DMSO. The plates
were incubated for 48 hours at 37C in an atmosphere of 5% CO2
and 90% relative humidity. Thereafter, 50 mL of chilled 50% TCAwas
gently added to each well of the plate, making a ﬁnal concentration
of 10%. The plates were incubated at 4C for 1 hour to ﬁx the cells
attached to the bottom of the wells. The plates were then washed
ﬁve or six times with distilled water and thereafter air-dried. To
each well, 100 mL of SRB dye (0.4% w/v in 1% acetic acid) was added
and left at room temperature for 30 minutes. Thereafter, the plates
were washed with 1% acetic acid. The plates were again air-dried
and 100 mL of Tris buffer (10mM; pH 10.5) was added to each
well. The plates were shaken gently for 10e15 minutes on a me-
chanical shaker. The optical density of the plate wells was recordedAverage tumor volume of controls Average tumor volume of treated animals
Average tumor volume of controls
 100with a microplate reader at 540 nm and data were maintained.
Growth inhibition was calculated as the percent survival of treated
cells over control cells  100 (T/C%).
% Growth inhibition ¼ 100 ½OD ðtest sampleÞ  OD ðblankÞ=
OD ðcontrolÞ  OD ðblankÞ  100:2.7. Evaluation of in vivo anticancer activity
2.7.1. Sarcoma-180 ascites model
This was carried out according to the method described by
Chashoo et al.23 Sarcoma-180 (S-180) cells were harvested from the
peritoneal cavity of Swiss albino mice, used for propagation,
harboring 8e10 days old ascitic tumors. On Day 0, 1  107 cells/
animal were injected intraperitoneally (i.p.) into the peritoneal
cavity of BALB/c mice of same sex. The tumor inoculated animals
were then randomized and divided into different groups based on
the treatment schedule, including one control (normal saline)
group and one standard drug (5-FU) group. FromDay 1 to Day 9, the
different treatment groups were administered i.p. AR-A001, AR-
A002, AR-A003 (100 mg/kg), and AR-A004 (80 mg/kg), 5-FU
(20 mg/kg), and normal saline (0.2 mL/mouse). On Day 12, all of
the animals were sacriﬁced under diethyl ether anesthesia and the
ascitic ﬂuid was collected from the peritoneal cavity of each mouse
for the evaluation of tumor weight, volume, and cell number. The
percent inhibition of tumor was calculated as under:Average number of cells in controls Average number of cells in tr
Average number of cells in controlsBased on the highest value of tumor growth inhibition and least
mortality, AR-A001 and AR-A004 were subjected to a graded dose
(80 mg/kg i.p., 100 mg/kg i.p., and 120 mg/kg i.p.) evaluation in this
model.
2.7.2. S-180 solid tumor model
This evaluation followed the same procedure outlined in the
ascites model except that tumor cells (1  107 cells/animal) were
injected intramuscularly (i.m.) into the right thigh of BALB/c mice of
the same sex on Day 0. Based on the effectiveness in the ascites
model, AR-A001 and AR-A004 were evaluated in this model at the
dose of 120 mg/kg and 110 mg/kg, respectively. The extracts were
administered i.p. Normal saline (0.2 mL/mouse) and 5-FU (20 mg/
kg) given i.p. served as control and standard drug, respectively. On
Day 13, the longest and shortest diameters of tumors were
measured with Vernier calipers and tumor volumewas determined
according to the formula:24,25
Tumor volume

mm3

¼

L  W2
.
2
Percent inhibition of tumor:2.7.3. L1210 lymphoid leukemia model
L1210 lymphocytic leukemia cells were harvested from the
peritoneal cavity of DBA/2 mice, used for propagation, harboring 7-
day-old tumors. On Day 0, 2.5  106 cells were injected i.p. into
CDF1 mice of the same sex. From Day 1 to Day 9, the different
treatment groups were administered i.p. AR-A001 and AR-A004
(100 mg/kg), 5-FU (20 mg/kg), and normal saline (0.2 mL/mouse).
The animals were observed for mortality and the mean survival
time (MST, days) was calculated as given below:
P
Sþ 6S5  19NT
S5 NT
where S5 ¼ number of survivors on Day 5, ƩS ¼ sum of daily sur-
vivors from Day 6 to Day 18, and NT ¼ number of no takes (survi-
vors beyond Day 18).
T=C% ¼ ðMSTTreatment=MSTControlÞ  100
where T¼mean survival time (MST, days) of the drug treated mice,
C¼mean survival time (MST, days) of untreated control animals, T/
C% < 125% ¼ toxic/inactive, and T/C% > 125% ¼ signiﬁcant anti-
leukemic effect.262.8. Statistical analysis
Results are expressed as mean ± standard error of the mean.
Data were analyzed using one-way analysis of variance followed byeated animals 100
Fig. 3. In vitro cytotoxic activity of AR-A003 against various human cancer cells lines in
the sulforhodamine B assay. Estimated IC50 values are NA, NA, >100 mg/ml, >100 mg/ml,
>100 mg/ml, and 93 mg/ml for A549, HCT-116, PC3, A431, HeLa, and THP-1, respectively.
Samples were assayed in quadruplicate. Values are mean ± standard deviation.
NA ¼ not active.
Fig. 1. In vitro cytotoxic activity of AR-A001 against various human cancer cells lines in
the sulforhodamine B assay. Estimated IC50 values are 20 mg/ml, 22 mg/ml, 3 mg/ml,
>100 mg/ml, >100 mg/ml, and 24 mg/ml for A549, HCT-116, PC3, A431, HeLa, and THP-1,
respectively. Samples were assayed in quadruplicate. Values are mean ± standard
deviation.
A.J. Akindele et al. / Journal of Traditional and Complementary Medicine 5 (2015) 35e4138Dunnett's multiple comparison test using GraphPad Prism 5
(GraphPad Software Inc., CA, USA). Values were considered signif-
icant at p < 0.05.
3. Results
3.1. In vitro cytotoxic activity
Figs. 1e4 show the effects of AR-A001, AR-A002, AR-A003, and
AR-A004, respectively, against the human cancer cell lines used in
this study. AR-A001 produced signiﬁcant cytotoxic activity against
A549, HCT-116, PC3, and THP-1 human cancer cell lines with IC50
values of 20 mg/mL, 22 mg/mL, 3 mg/mL, and 24 mg/mL, respectively.
AR-A002 and AR-A003 did not elicit signiﬁcant activity against the
human cancer cell lines used in this study, with IC50 values
generally > 100 mg/mL. AR-A004 showed signiﬁcant and consistent
cytotoxic activity against all the human cancer cell lines in this
study, with IC50 values of 26 mg/mL,19.5 mg/mL,12 mg/mL, 28 mg/mL,
30 mg/mL, and 22 mg/mL for A549, HCT-116, PC3, A431, HeLa, and
THP-1, respectively.
3.2. In vivo anticancer activity of AR extracts against S-180 ascites
in BALB/c mice
Initial screening results for the effects of AR extracts on the S-180
ascites model in mice are shown in Table 1. AR-A001 (100 mg/kg)
and AR-A004 (80 mg/kg) elicited 73.56% and 72.16% inhibition in
tumor growthwith nomortality recorded. These effectswere highly
signiﬁcant (p < 0.001) in respect of the number of tumor cells pre-
sent in the peritoneal cavity of treated mice as compared to control
mice, but signiﬁcantly lower (p < 0.05, 0.01) as compared to 5-FUFig. 2. In vitro cytotoxic activity of AR-A002 against various human cancer cells lines in
the sulforhodamine B assay. Estimated IC50 values are >100 mg/ml, >100 mg/ml,
>100 mg/ml, 67 mg/ml, 66 mg/ml, and >100 mg/ml for A549, HCT-116, PC3, A431, HeLa,
and THP-1, respectively. Samples were assayed in quadruplicate. Values are
mean ± standard deviation.(97.84% inhibition). AR-A002 and AR-A003 (100 mg/kg) elicited
80.66% and 77.24% tumor growth inhibition with mortalities of
57.14% and 71.43%, respectively. As shown in Table 2, the effects of
AR-A001 and AR-A004 were dose-dependent with peak tumor cell
growth inhibitory effects elicited at a dose of 120mg/kg (79.51% and
89.98% inhibition, respectively). However, mortality was not recor-
ded at this dose for AR-A001,while it was 60% in respect of AR-A004.
3.3. In vivo anticancer activity of AR-A001 and AR-A004 extracts
against S-180 solid tumor in BALB/c mice
The effects of active extracts against S-180 solid tumor are shown
inTable 3. AR-A001 (120mg/kg) andAR-A004 (110mg/kg) produced
a signiﬁcant reduction (p < 0.05) in the body weight of mice and
signiﬁcant inhibition in tumor growth on Day 9 and Day 13 as
compared to control animals. The inhibition in solid tumor growth
produced by AR-A001 was reduced from 31.81% on Day 9 to 29.45%
on Day 13. The effect of AR-A001 on tumor volume on Day 9 was
signiﬁcantly lower (p < 0.05) than that produced by 5-FU (63.39%)
while the effect of the extract on Day 13 was comparable and not
signiﬁcantly different (p > 0.05) from that elicited by 5-FU (50.18%).
Tumor growth inhibition produced by AR-A004 reduced from
55.74% on Day 9 to 50.50% on Day 13, with the later effect being
comparable andnot signiﬁcantlydifferent (P>0.05) relative to 5-FU.
3.4. Effects of AR-A001 and AR-A004 extracts against L1210
lymphoid leukemia in CDF1 mice
The effects of AR-A001 and AR-A004 (100 mg/kg) on L1210
lymphoid leukemiamodel are shown in Table 4. AR-A001 increased
the MST from 9 days in control to 19 days, corresponding to aFig. 4. In vitro cytotoxic activity of AR-A004 against various human cancer cells lines in
the sulforhodamine B assay. Estimated IC50 values are 26 mg/ml, 19.5 mg/ml, 12 mg/ml,
28 mg/ml, 30 mg/ml and 22 mg/ml for A549, HCT-116, PC3, A431, HeLa, and THP-1,
respectively. Samples were assayed in quadruplicate. Values are mean ± standard
deviation.
Table 1
Effects of Aristolochia ringens (AR) extracts against sarcoma-180 (ascites) in BALB/c mice.
Treatments Dose (mg/kg) Body weight (g) Day 12 Tumor growth
inhibition (%)
Mortality
(%)
Day 1 Day 5 Day 9 Body weight (g) Weight of
tumor (g)
Volume of ascitic
ﬂuid (mL)
Number of tumor
cells ( 107)
Normal saline (0.2 mL/mouse) 22.91 ± 0.74 24.82 ± 0.86 28.64 ± 1.19 29.36 ± 1.44 9.73 ± 1.00 9.88 ± 0.96 277.86 ± 37.20 0 0
5-FU 20 21.14 ± 0.55* 20.86 ± 0.63*** 17.71 ± 0.84*** 16.60 ± 0.75*** 0.50 ± 0.21*** 0.52 ± 0.22*** 6.00 ± 2.45*** 97.84 0
AR-A001 100 20.43 ± 0.48** 20.86 ± 0.55*** 21.43 ± 0.95***,## 21.43 ± 1.00***,## 5.86 ± 1.37*,## 6.01 ± 1.35*,## 73.47 ± 15.71***,## 73.56 0
AR-A002 100 20.57 ± 0.37** 18.43 ± 0.20***,# 16.83 ± 0.48*** 16.67 ± 1.33*** 1.85 ± 0.98*** 2.00 ± 1.04*** 53.75 ± 27.17*** 80.66 57.14
AR-A003 100 20.71 ± 0.42* 17.71 ± 0.42***,### 16.50 ± 0.22*** 15.00 ± 3.00* 2.71 ± 2.71 2.75 ± 2.75 63.25 ± 63.25 77.24 71.43
AR-A004 80 21.00 ± 0.62* 20.14 ± 0.55c 18.57 ± 0.65*** 17.29 ± 1.32*** 2.56 ± 0.71***,# 2.73 ± 0.74***,# 77.34 ± 26.44***,# 72.16 0
Data are presented as mean ± standard error of the mean (n ¼ 7, n ¼ 11 for control).
*p < 0.05, **p < 0.01, ***p < 0.001 versus normal saline.
#p < 0.05, ##p < 0.01, ###p < 0.001 versus 5-FU (one-way analysis of variance followed by Dunnett's multiple comparison test).
5-FU ¼ 5-ﬂuorouracil.
Table 2
Effects of AR-A001 (80 mg/kg, 120 mg/kg) and AR-A004 extracts (100 mg/kg, 120 mg/kg) against sarcoma-180 (ascites) in BALB/c mice.
Treatments Dose (mg/kg) Body weight (g) Day 12 Tumor growth
inhibition (%)
Mortality
(%)
Body weight (g) Weight of
tumor (g)
Volume of ascitic
ﬂuid (mL)
Number of tumor
cells ( 107)
Day 1 Day 5 Day 9
Normal saline (0.2 mL/mouse) 21.40 ± 0.75 23.80 ± 0.86 27.20 ± 1.24 27.60 ± 1.12 9.81 ± 1.01 9.96 ± 0.77 474.25 ± 45.26 0 0
5-FU 20 21.20 ± 0.58 22.60 ± 0.75 21.40 ± 1.08** 20.60 ± 1.44** 0.50 ± 0.22*** 0.48 ± 0.22*** 10.00 ± 4.18*** 97.89 0
AR-A001 80 20.80 ± 0.66 21.80 ± 1.07 22.60 ± 1.69* 23.00 ± 1.70* 4.91 ± 1.06**,## 5.10 ± 1.07**,## 138.55 ± 30.42***,## 70.79 0
120 20.80 ± 0.66 21.20 ± 0.80* 21.20 ± 1.07** 20.80 ± 1.93* 3.71 ± 1.08**,# 3.70 ± 1.12**,# 97.18 ± 31.07***,# 79.51 0
AR-A004 100 20.80 ± 0.66 20.20 ± 1.07* 18.60 ± 1.03***,# 18.60 ± 1.12*** 2.35 ± 0.92*** 2.52 ± 0.99*** 55.14 ± 22.88*** 88.37 0
120 20.80 ± 0.66 20.80 ± 0.97* 19.60 ± 1.50** 22.50 ± 2.50 2.36 ± 2.36 2.50 ± 2.50 47.50 ± 47.50** 89.98 60
Data are presented as mean ± standard error of the mean (n ¼ 5).
*p < 0.05, **p < 0.01, ***p < 0.001 versus normal saline.
#p < 0.05, ##p < 0.01 versus 5-FU (one-way analysis of variance followed by Dunnett’s multiple comparison test).
5-FU ¼ 5-ﬂuorouracil.
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Table 3
Effects of AR-A001 and AR-A004 extract against sarcoma-180 (solid) tumor in BALB/c mice.
Treatments Dose (mg/kg) Body weight (g) Day 9 Day 13
Day 1 Day 5 Day 9 Day 13 Tumor volume (mm3) Inhibition
(%)
Tumor volume
(mm3)
Inhibition
(%)
Normal
saline
(0.2 mL/mouse) 21.80 ± 0.58 23.00 ± 0.55 23.80 ± 0.58 24.00 ± 0.32 1848.50 ± 108.31 0.00 2283.50 ± 136.58 0.00
5-FU 20 21.80 ± 0.58 20.60 ± 1.17 18.80 ± 2.08* 19.80 ± 2.15 676.80 ± 188.15*** 63.39 1137.60 ± 247.45** 50.18
AR-A001 120 20.80 ± 0.86 21.20 ± 1.02 20.60 ± 1.21* 20.80 ± 1.02* 1260.40 ± 237.90*,# 31.81 1611.00 ± 290.72* 29.45
AR-A004 110 20.80 ± 0.86 20.20 ± 1.50 19.80 ± 1.39* 19.60 ± 1.21** 818.10 ± 124.32*** 55.74 1130.40 ± 137.88*** 50.50
Values are mean ± standard error of the mean (n ¼ 5).
*p < 0.05, **p < 0.01, ***p < 0.001 versus normal saline.
#p < 0.05 versus 5-FU (one-way analysis of variance followed by Dunnett’s multiple comparison test).
5-FU ¼ 5-ﬂuorouracil.
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respect of AR-A004, MST was 14 days compared to 9 days for
control, corresponding to 155.56% increase in MST.
4. Discussion
Cancer is the leading cause of death in economically developed
countries and the second leading cause of death in developing
countries.27 The burden of cancer is increasing in economically
developing countries as a result of population aging and growth,
and adoption of cancer-associated lifestyle choices including
smoking, physical inactivity and “westernized” diets.3 Schwarts-
mann et al6 stated that the total number of new cases of cancer will
rise from 10 million in year 2000 by approximately 25% in each
decade, reaching 24 million new cases/year in the year 2050. The
total number of deaths will rise from 6 million in the year 2000 to
10 million in 2020, and to > 16 million in the year 2050.28,29
Furthermore, it was reported that in the year 2050, there will be
17 million new cases of cancer in less developed countries, while
only 7million new cases of cancer will occur in themore developed
countries, with the assertion that public health authorities should
expect cancer to become a major challenge not only in developed
countries but especially in developing countries as well.29e31
The major challenges associated with currently available anti-
cancer agents include selectivity, toxicity, resistance, and develop-
ment of a secondary malignancy. These drawbacks have motivated
the search for newer, more efﬁcacious, and better tolerated anti-
tumor drugs, with natural products, especially plants, offering an
inexhaustible reservoir for new drug discovery and development.
In this study, the DCM:MeOH extract of the root of AR (AR-A004)
was signiﬁcantly active against PC3, HCT-116, THP-1, A549, A431,
and HeLa human cancer cell lines with an IC50 range of 12e30 mg/
mL in the SRB cytotoxicity assay. Based on the recommendation of
the National Cancer Institute (NCI, USA), 30 mg/mL is the upper IC50
limit considered promising for puriﬁcation of a crude extract.32 The
ethanol extract (AR-A001) was also found to be signiﬁcantly activeTable 4
Effects of AR-A001 and AR-A004 extracts against L1210 lymphoid leukemia in CDF1
mice.
Treatments Dose (mg/kg) Mean survival
time (days)
% Increase in
mean survival
time
Inference
Normal saline (0.2 mL/mouse) 9 e e
5-FU 20 19 211.11 Signiﬁcant
activity
AR-A001 100 19 211.11 Signiﬁcant
activity
AR-A004 100 14 155.56 Signiﬁcant
activity
5-FU ¼ 5-ﬂuorouracil.
T/C% < 125% ¼ toxic/inactive; T/C% > 125% ¼ signiﬁcant antileukemic effect.against PC3, A549, HCT-116, and THP-1 cell lines, with an IC50 range
of 3e24 mg/mL. AR-A004 but not AR-A001 was found to be active in
the S-180 solid tumor model (50.50% tumor growth inhibition at a
dose of 110 mg/kg relative to a value of 50.18% for 5-FU at 20 mg/
kg). The initial activity against S-180 ascites was statistically sig-
niﬁcant (72.16%, 88.37%, and 89.98% tumor growth inhibition at
doses of 80 mg/kg, 100 mg/kg, and 120 mg/kg as compared to
97.89% for 5-FU at 20 mg/kg). The dose of AR-A004 used in the solid
tumor model was 110 mg/kg, because although the highest tumor
growth inhibitory activity was observed at a dose of 120 mg/kg,
mortality was 60% at this dose. AR-A001 also produced dose-
dependent antitumor activity in the S-180 ascites model, with tu-
mor growth inhibition values of 73.56%, 70.79%, and 79.51% at
doses of 80 mg/kg, 100 mg/kg, and 120 mg/kg, respectively. How-
ever, the tumor growth inhibition value was just 29.45% in the S-
180 solid tumor model for AR-A001. Both AR-A001 and AR-A004
(100 mg/kg) were also signiﬁcantly active in the L1210 lymphoid
leukemia model (T/C 211.11 and 155.56%, respectively, relative to
211.11% for 5-FU), with AR-A001 showing greater activity, compa-
rable to 5-FU, in this model. This is in view of the interpretation by
Todorova et al26 that T/C% value < 125% indicates toxicity/inactivity
while a value > 125% depicts a signiﬁcant antileukemic effect. The
results obtained in this study established for the ﬁrst time the
in vitro and in vivo anticancer activity of AR with the DCM:MeOH
and ethanolic root extracts showing signiﬁcant activity in the solid
tumor and leukemia models used in this study.
In this study, AR-A002 and AR-A003 did not elicit signiﬁcant
activity against the human cancer cell lines used, with IC50 values
generally > 100 mg/mL. However, these extracts elicited signiﬁcant
tumor growth inhibition in the S-180 ascites model, although
mortality was signiﬁcant. It should be noted that inactivity in vitro
does not automatically translate to inactivity in vivo, because in
some cases, inactive phytochemical principles may need metabolic
activation which is not possible under the in vitro environment.
Other studies have reported the anticancer activity of the DCM
and MeOH,17 chloroform,33,34 and aqueous19 extracts of other
species of the Aristolochia family. The anticancer activity of various
species of Aristolochia has been reported but not of AR. Voloudakis-
Baltatzis et al35 evaluated the anticancer activity of the Greek herb
substances IBV-BK (Aristolochia, Iska) on human primary cultures
derived from malignant and nonmalignant breast tissues in vitro
and in vivo in rats with Walker carcinoma. Based on ﬁndings in the
study, the authors concluded that IBK-BK, with Aristolochia as one
of the constituents, possesses potent anticancer activity in vitro and
in vivo. Mongelli et al17 investigated the cytotoxic and DNA inter-
action of extracts of Argentinean medicinal plants including Aris-
tolochia triangularis. Aristolochia triangularis, along with other
plants, was established to contain cytotoxic compounds against KB
cells based on inhibition of growth of crown gall tumors. The assay
employed showed good correlation with the 3PS (in vivo murine
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gated the antitumor effect of the whole plant extract of Aristolochia
indica against Ehrlich ascites carcinoma in mice. The crude chlo-
roform extract resulted in signiﬁcant tumor cell growth inhibition
and increased the MST. The root extract of Aristolochia indica has
been reported to inhibit the growth of human CA-755 and HeLa
cells and to be effective against adenocarcinoma.37 Chaouki et al34
investigated the antiproliferative effect of four different polarity
extracts of Aristolochia baetica on the human breast cancer cell line
MCF-7 and reported the chloroform extract to be the most active.
Benarba et al19 investigated the cytotoxic and apoptogenic activ-
ities of the aqueous extract of Aristolochia longa in Burkitt's lym-
phoma BL41 cells by ﬂow cytometry. Based on the signiﬁcant
efﬁcacy demonstrated in the study, the aqueous extract of Aristo-
lochia longa was reported to be a promising source of novel treat-
ment of Burkitt's and other lymphomas. The establishment of
anticancer activity of AR in this study is in agreement with the
report of antiproliferative effects for other species of the genus.
5. Conclusion
In conclusion, the ﬁndings in this study suggest that the etha-
nolic (AR-A001) and DCM:MeOH (AR-A004) root extracts of AR
possess signiﬁcant anticancer activities in vitro and in vivo. AR-A001
was signiﬁcantly active in the S-180 ascites and L1210 lymphoid
leukemia in vivo models. AR-A004 was additionally signiﬁcantly
active in the S-180 solid tumor model. Further extensive studies are
required to afford the identiﬁcation, isolation, and characterization
of speciﬁc phytomolecules responsible for bioactivities observed in
this study and their inherent mechanism(s) of action.
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